Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402124 | 1.00 | DHFR (0.48) | DHFRFFAR1FFAR4TSHRPPARG | |
| SCHEMBL1229002 | 0.96 | DHFR (0.53) | DHFRFFAR1PPARGPPARDPPARA | |
| SCHEMBL2046234 | 0.94 | PPARA (0.52) | DHFRFFAR1PPARGPPARDPPARA | |
| SCHEMBL30215712 | 0.89 | CD274 (0.46) | DHFRFFAR1 | |
| SCHEMBL16301494 | 0.89 | PDE3B (0.43) | FFAR1 | |
| Aminodiphenylmethane SCHEMBL1963354 | 0.88 | NR1H3 (0.46) | DHFRFFAR1FFAR4PTPN1 | |
| SCHEMBL17593842 | 0.87 | DHFR (0.50) | DHFRFFAR1FFAR4TSHRPPARG | |
| SCHEMBL10335441 | 0.85 | LMNA (0.53) | DHFRFFAR1FFAR4TSHRPPARG | |
| SCHEMBL12036216 | 0.85 | CNR1 (0.48) | — | |
| SCHEMBL5953370 | 0.84 | FFAR1 (0.45) | DHFRFFAR1FFAR4TSHRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378267-B2 | Synthesis of FMOC-protected morpholino monomers and oligomers | ENTRADA THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-20230097585-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERS | ENTRADA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | claimed |
| EP-3405476-B1 | METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2022-05-18 | — | — | EP | claimed |
| US-11236123-B2 | Method for preparation of peptides with psWang linker | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2022-02-01 | — | — | US | claimed |
| CN-104619717-B | The synthesis of β-corner simulation peptide cyclic compound | 米梅奥亨制药公司 | 2019-04-02 | — | — | CN | claimed |
| US-20180259510-A1 | NON-COVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL | NATIONAL SCIENCE FOUNDATION | 2018-09-13 | — | — | US | claimed |
| US-20160041158-A1 | NON-CONVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL | NATIONAL SCIENCE FOUNDATION | 2016-02-11 | — | — | US | claimed |
| CN-104619717-A | Synthesis of beta-turn peptidomimetic cyclic compounds | MIMETOGEN PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | claimed |
| WO-2014144383-A1 | NON-COVALENT PATTERNED CHEMICAL FEATURES AND USE THEREOF IN MALDI-BASED QUALITY CONTROL | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2014-09-18 | — | — | WO | claimed |
| JP-4625603-B2 | — | — | 2011-02-02 | — | — | JP | claimed |
| US-20020173051-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002081078-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1214336-A1 | SYNTHESIS OF TEMPLATE-FIXED BETA-HAIRPIN LOOP MIMETICS | Universität Zürich (CH) | 2002-06-19 | — | — | EP | claimed |
| WO-2002000337-A1 | A CHROMATOGRAPHY MATERIAL AND A PROCESS OF MANUFACTURING THAT MATERIAL | BIA SEPARATIONS D.O.O. (SI) | 2002-01-03 | — | — | WO | claimed |
| WO-2001016161-A1 | SYNTHESIS OF TEMPLATE-FIXED β-HAIRPIN LOOP MIMETICS | Universität Zürich (CH) | 2001-03-08 | — | — | WO | claimed |
| EP-1018526-A1 | Process for preparing polyurethane foam | CK WITCO CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| EP-0929567-A1 | IMPROVED SOLID-PHASE PEPTIDE SYNTHESIS AND AGENT FOR USE IN SUCH SYNTHESIS | Zealand Pharmaceuticals A/S (DK) | 1999-07-21 | — | — | EP | claimed |
| US-5858534-A | FOR SOLID PHASE SYNTHESIS; POLYSTYRENE COATED METAL OXIDE PARTICLES DISPERSED IN POLYSTYRENE MATRIX | SOLID PHASE SCIENCES CORP. (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998011125-A1 | IMPROVED SOLID-PHASE PEPTIDE SYNTHESIS AND AGENT FOR USE IN SUCH SYNTHESIS | ZEALAND PHARMACEUTICALS A/S (DK) | 1998-03-19 | — | — | WO | claimed |
| EP-0608779-A1 | Apparatus for peptide synthesis | SHIMADZU CORPORATION (JP) | 1994-08-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173051-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | DHFR 1700/4885FFAR1 3857/4885FFAR4 3631/4885 |
| US-12378267-B2 | Synthesis of FMOC-protected morpholino monomers and oligomers | PMM2, PHAX, PTBP3 | DHFR 1130/4885FFAR1 3944/4885FFAR4 4008/4885 |
| US-11236123-B2 | Method for preparation of peptides with psWang linker | VIP, GLP1R, IAPP | DHFR 2354/4885FFAR1 932/4885FFAR4 645/4885 |
| US-20230097585-A1 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERS | PMM2, PHAX, PTBP3 | DHFR 1130/4885FFAR1 3944/4885FFAR4 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.